Literature DB >> 21987480

Upper limits of normal for alanine aminotransferase activity in the United States population.

Constance E Ruhl1, James E Everhart.   

Abstract

UNLABELLED: Alanine aminotransferase (ALT) is an important test for liver disease, yet there is no generally accepted upper limit of normal (ULN) in the United States. Furthermore, the ability of ALT to differentiate persons with and without liver disease is uncertain. We examined cut-offs for ALT for their ability to discriminate between persons with positive hepatitis C virus (HCV) RNA and those at low risk for liver injury in the U.S. population. Among adult participants in the 1999-2008 U.S. National Health and Nutrition Examination Survey, 259 were positive for serum HCV RNA and 3,747 were at low risk for liver injury (i.e., negative HCV RNA and hepatitis B surface antigen, low alcohol consumption, no evidence of diabetes, and normal body mass index and waist circumference). Serum ALT activity was measured centrally. Maximum correct classification was achieved at ALT = 29 IU/L for men (88% sensitivity, 83% specificity) and 22 IU/L (89% sensitivity, 82% specificity) for women. The cut-off for 95% sensitivity was an ALT = 24 IU/L (70% specificity) for men and 18 IU/L (63% specificity) for women. The cut-off for 95% specificity was ALT = 44 IU/L (64% sensitivity) for men and 32 IU/L (59% sensitivity) for women. The area under the curve was 0.929 for men and 0.915 for women. If the cut-offs with the best correct classification were applied to the entire population, 36.4% of men and 28.3% of women would have had abnormal ALT.
CONCLUSION: ALT discriminates persons infected with HCV from those at low risk of liver disease, but would be considered elevated in a large proportion of the U.S. population.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21987480      PMCID: PMC3268908          DOI: 10.1002/hep.24725

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  17 in total

1.  Common reference intervals for aspartate aminotransferase (AST), alanine aminotransferase (ALT) and γ-glutamyl transferase (GGT) in serum: results from an IFCC multicenter study.

Authors:  Ferruccio Ceriotti; Joseph Henny; Josep Queraltó; Shen Ziyu; Yeşim Özarda; Baorong Chen; James C Boyd; Mauro Panteghini
Journal:  Clin Chem Lab Med       Date:  2010-10-29       Impact factor: 3.694

2.  Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study.

Authors:  Revital Kariv; Moshe Leshno; Anat Beth-Or; Hana Strul; Laurie Blendis; Ehud Kokia; Dina Noff; Shira Zelber-Sagie; Bracha Sheinberg; Ran Oren; Zamir Halpern
Journal:  Liver Int       Date:  2006-05       Impact factor: 5.828

3.  Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group.

Authors:  A Piton; T Poynard; F Imbert-Bismut; L Khalil; J Delattre; E Pelissier; N Sansonetti; P Opolon
Journal:  Hepatology       Date:  1998-05       Impact factor: 17.425

4.  Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels.

Authors:  Brent A Neuschwander-Tetri; Aynur Unalp; Michael H Creer
Journal:  Arch Intern Med       Date:  2008-03-24

5.  What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI).

Authors:  Helmi M'Kada; Mona Munteanu; Hugo Perazzo; Yen Ngo; Nittia Ramanujam; Françoise Imbert-Bismut; Vlad Ratziu; Dominique Bonnefont-Rousselot; Bernard Souberbielle; Ina Schuppe-Koistinen; Thierry Poynard
Journal:  Regul Toxicol Pharmacol       Date:  2011-04-24       Impact factor: 3.271

6.  Healthy range for serum ALT and the clinical significance of "unhealthy" normal ALT levels in the Korean population.

Authors:  Hyun Seok Kang; Soon Ho Um; Yeon Seok Seo; Hyonggin An; Kwang Gyun Lee; Jong Jin Hyun; Eun Sun Kim; Sung Chul Park; Bora Keum; Ji Hoon Kim; Hyung Joon Yim; Yoon Tae Jeen; Hong Sik Lee; Hoon Jai Chun; Chang Duck Kim; Ho Sang Ryu
Journal:  J Gastroenterol Hepatol       Date:  2011-02       Impact factor: 4.029

7.  The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.

Authors:  Gregory L Armstrong; Annemarie Wasley; Edgar P Simard; Geraldine M McQuillan; Wendi L Kuhnert; Miriam J Alter
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

8.  Healthy ranges of serum alanine aminotransferase levels in Iranian blood donors.

Authors:  Mehdi Mohamadnejad; Akram Pourshams; Reza Malekzadeh; Ashraf Mohamadkhani; Afsaneh Rajabiani; Ali Ali Asgari; Seyed Meysam Alimohamadi; Hadi Razjooyan; Mansooreh Mamar-Abadi
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

9.  Updated definitions of healthy ranges for serum alanine aminotransferase levels.

Authors:  Daniele Prati; Emanuela Taioli; Alberto Zanella; Emanuela Della Torre; Sonia Butelli; Emanuela Del Vecchio; Luciana Vianello; Francesco Zanuso; Fulvio Mozzi; Silvano Milani; Dario Conte; Massimo Colombo; Girolamo Sirchia
Journal:  Ann Intern Med       Date:  2002-07-02       Impact factor: 25.391

10.  Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study.

Authors:  Hyeon Chang Kim; Chung Mo Nam; Sun Ha Jee; Kwang Hyub Han; Dae Kyu Oh; Il Suh
Journal:  BMJ       Date:  2004-03-17
View more
  45 in total

1.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Authors:  Norah A Terrault; Anna S F Lok; Brian J McMahon; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; Robert S Brown; Natalie H Bzowej; John B Wong
Journal:  Hepatology       Date:  2018-04       Impact factor: 17.425

2.  Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans.

Authors:  Fasiha Kanwal; Jennifer R Kramer; Zhigang Duan; Xiaoying Yu; Donna White; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-17       Impact factor: 11.382

3.  Comparison of hepatitis C virus testing strategies: birth cohort versus elevated alanine aminotransferase levels.

Authors:  Bryce D Smith; Anthony K Yartel
Journal:  Am J Prev Med       Date:  2014-09       Impact factor: 5.043

4.  Increased liver markers are associated with higher risk of type 2 diabetes.

Authors:  Sun-Hye Ko; Myong Ki Baeg; Kyung-Do Han; Seung-Hyun Ko; Yu-Bae Ahn
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

Review 5.  Updates on Chronic HBV: Current Challenges and Future Goals.

Authors:  Hannah M Lee; Bubu A Banini
Journal:  Curr Treat Options Gastroenterol       Date:  2019-06

6.  ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.

Authors:  Paul Y Kwo; Stanley M Cohen; Joseph K Lim
Journal:  Am J Gastroenterol       Date:  2016-12-20       Impact factor: 10.864

7.  Elevated liver enzymes in individuals with undiagnosed diabetes in the U.S.

Authors:  Christie Y Jeon; Christian K Roberts; Catherine M Crespi; Zuo-Feng Zhang
Journal:  J Diabetes Complications       Date:  2013-05-14       Impact factor: 2.852

8.  Impacts of common factors of life style on serum liver enzymes.

Authors:  Joanna Danielsson; Päivikki Kangastupa; Tiina Laatikainen; Mauri Aalto; Onni Niemelä
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

9.  Identifying practice gaps to optimize medical care for patients with nonalcoholic fatty liver disease.

Authors:  Amanda C Wieland; Matthew Quallick; Aimee Truesdale; Pamela Mettler; Kiran M Bambha
Journal:  Dig Dis Sci       Date:  2013-07-11       Impact factor: 3.199

10.  Long-Term Outcomes After Drug-Induced Liver Injury.

Authors:  Paul H Hayashi; Einar S Bjornsson
Journal:  Curr Hepatol Rep       Date:  2018-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.